Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration.

Changes in non-native aggregation mechanisms of an anti-streptavidin (anti-SA) IgG1 antibody were determined over a wide range of pH and [NaCl] under accelerated (high temperature) conditions, using a combination of calorimetry, chromatography, static light scattering, dye binding, and spectroscopy (fluorescence, infra-red, and circular dichroism). Aggregation rates were strongly influenced by conformational stability of at least the Fab regions, but were only weakly affected by changes in electrostatic colloidal interactions. This was in contrast to the effects of electrostatic interactions on aggregate growth, as the dominant growth mechanism shifted dramatically with pH and [NaCl]. Pre-formed aggregates also displayed a reversible cloud-point boundary that quantitatively aligned with the overall pattern of aggregation mechanisms as a function of pH and [NaCl], suggesting an underlying thermodynamic transition may dictate whether molecular aggregates will coalesce into macroscopic particles. Structural changes upon unfolding and aggregation were also sensitive to pH and [NaCl]. Interestingly, Thioflavin T binding was essentially indistinguishable for aggregates formed in different pH and [NaCl] conditions, however, the other assays indicated notable differences across different solvent conditions. This suggests that the overall degree of conformational change during aggregation can be influenced by electrostatic interactions, but suggests caution in interpreting whether available techniques detect changes that are directly relevant to the mechanism(s) of aggregate formation and growth.

[1]  C. Winsor,et al.  The Gompertz Curve as a Growth Curve. , 1932, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Erinc Sahin,et al.  Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. , 2011, International journal of pharmaceutics.

[3]  Sandeep Kumar,et al.  Potential aggregation prone regions in biotherapeutics , 2009, mAbs.

[4]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[5]  William F. Weiss,et al.  Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. , 2012, Journal of pharmaceutical sciences.

[6]  Massimo Morbidelli,et al.  Population balance modeling of antibodies aggregation kinetics. , 2012, The journal of physical chemistry. B.

[7]  C. Roberts,et al.  Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. , 2011, Journal of pharmaceutical sciences.

[8]  David C. James,et al.  Therapeutic proteins : methods and protocols , 2005 .

[9]  Babatunde A. Ogunnaike,et al.  Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. , 2010, Journal of pharmaceutical sciences.

[10]  V. Subramaniam,et al.  Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .

[11]  Glyn L. Devlin,et al.  Amyloid fibril-like structure underlies the aggregate structure across the pH range for beta-lactoglobulin. , 2009, Biophysical journal.

[12]  Yi Li,et al.  High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.

[13]  Christopher J Roberts,et al.  Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions. , 2011, Journal of pharmaceutical sciences.

[14]  Theodore W Randolph,et al.  Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. , 2009, Journal of pharmaceutical sciences.

[15]  S. Cohen,et al.  Antibody structure , 2006 .

[16]  C. Roberts,et al.  Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. , 2007, Biochemistry.

[17]  Theodore W Randolph,et al.  Aggregation of a monoclonal antibody induced by adsorption to stainless steel , 2010, Biotechnology and bioengineering.

[18]  Sandeep Yadav,et al.  Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. , 2010, Journal of pharmaceutical sciences.

[19]  A. Lenhoff,et al.  A consistent experimental and modeling approach to light-scattering studies of protein-protein interactions in solution. , 2005, Biophysical journal.

[20]  A. Grillo,et al.  Conformational origin of the aggregation of recombinant human factor VIII. , 2001, Biochemistry.

[21]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[22]  Liqiang Lisa Zhou,et al.  Impact of short range hydrophobic interactions and long range electrostatic forces on the aggregation kinetics of a monoclonal antibody and a dual-variable domain immunoglobulin at low and high concentrations. , 2011, International journal of pharmaceutics.

[23]  A. Vermeer,et al.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.

[24]  Deborah S. Goldberg,et al.  Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.

[25]  W. Gombotz,et al.  Minimization of recombinant human Flt3 ligand aggregation at the Tm plateau: a matter of thermal reversibility. , 1999, Biochemistry.

[26]  Christopher J Roberts,et al.  Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. , 2011, Journal of pharmaceutical sciences.

[27]  William F. Weiss,et al.  Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. , 2009, Journal of pharmaceutical sciences.

[28]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[29]  M. Shirts,et al.  Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange , 2011, Pharmaceutical Research.

[30]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[31]  Yatin R. Gokarn,et al.  Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. , 2010, Journal of pharmaceutical sciences.

[32]  Hollis Lau,et al.  Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. , 2010, Biochemistry.

[33]  Erinc Sahin,et al.  Relating particle formation to salt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A. , 2012, Journal of pharmaceutical sciences.

[34]  C. Roberts,et al.  Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. , 2009, The journal of physical chemistry. B.

[35]  Heather Franey,et al.  Increased aggregation propensity of IgG2 subclass over IgG1: Role of conformational changes and covalent character in isolated aggregates , 2010, Protein science : a publication of the Protein Society.

[36]  A. Fink Protein aggregation: folding aggregates, inclusion bodies and amyloid. , 1998, Folding & design.

[37]  Vincenzo Martorana,et al.  Aggregation of a multidomain protein: A coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress , 2010, Protein science : a publication of the Protein Society.

[38]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[39]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[40]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[41]  Christopher J Roberts,et al.  Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. , 2010, Journal of pharmaceutical sciences.

[42]  Massimo Morbidelli,et al.  On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. , 2012, Biophysical chemistry.

[43]  Wei Wang,et al.  Protein aggregation and its inhibition in biopharmaceutics. , 2005, International journal of pharmaceutics.

[44]  Pieter Bastiaan Ober Random Phenomena: Fundamentals of Probability and Statistics for Engineers , 2011 .

[45]  Christopher J Roberts,et al.  Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.

[46]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[47]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[48]  Ruth C. Carter,et al.  Principles , 2003, Law’s Reality.

[49]  A. Ginsburg Reversible, Thermally Induced Domain Unfolding in Oligomeric Proteins. Spectral and DSC measurements , 2000 .

[50]  Yi Li,et al.  Reexamining protein-protein and protein-solvent interactions from Kirkwood-Buff analysis of light scattering in multi-component solutions. , 2011, The Journal of chemical physics.

[51]  M. Manning,et al.  Aggregation of recombinant human interferon gamma: kinetics and structural transitions. , 1998, Journal of pharmaceutical sciences.

[52]  Linda O Narhi,et al.  High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. , 2011, Journal of pharmaceutical sciences.

[53]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  S. Demarest,et al.  A broad range of Fab stabilities within a host of therapeutic IgGs. , 2007, Biochemical and biophysical research communications.

[55]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[56]  Theodore W Randolph,et al.  Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. , 2009, Biochemistry.

[57]  P. Privalov Stability of proteins: small globular proteins. , 1979, Advances in protein chemistry.

[58]  Theodore W Randolph,et al.  Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. , 2002, Biochemistry.